Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Bernstein

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
Plos One|June 27, 2017
Enhanced light microscopy visualization of virus particles from Zika virus to filamentous ebolavirusesGeorge G Daaboul, David S Freedman, Steven M Scherr, et al.
Annals of Internal Medicine|March 5, 2004
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseStephanos J Hadziyannis, Hoel Sette, Timothy R Morgan, et al.
Cancer|January 19, 2021
Expenditures among young adults with acute lymphoblastic leukemia by site of careJulie A Wolfson, Smita Bhatia, Jill Ginsberg, et al.
Respiratory Research|May 31, 2020
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsGary T Ferguson, Nicola Brown, Chris Compton, et al.
Journal of Women'S Health (2002)|April 22, 2021
Sex-Based Differences in COVID-19 OutcomesAstha Tejpal, Eugenia Gianos, Jane Cerise, et al.
Journal of Viral Hepatitis|April 14, 2019
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosisFred Poordad, Shahriar Sedghi, Paul J Pockros, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 29, 2014
Management of acute loss of asthma control in the yellow zone: a practice parameterChitra Dinakar, John Oppenheimer, Jay Portnoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Modernizing Eligibility Criteria for Molecularly Driven TrialsEdward S Kim, David Bernstein, Susan G Hilsenbeck, et al.
The Science of the Total Environment|March 14, 2019
Using high-resolution residential greenspace measures in an urban environment to assess risks of allergy outcomes in childrenRebecca Gernes, Cole Brokamp, Glenn E Rice, et al.
Hepatology (Baltimore, Md.)|January 23, 2016
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized studyPaul Kwo, Norman Gitlin, Ronald Nahass, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Plos One|June 27, 2017
Enhanced light microscopy visualization of virus particles from Zika virus to filamentous ebolavirusesGeorge G Daaboul, David S Freedman, Steven M Scherr, et al.
Annals of Internal Medicine|March 5, 2004
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseStephanos J Hadziyannis, Hoel Sette, Timothy R Morgan, et al.
Cancer|January 19, 2021
Expenditures among young adults with acute lymphoblastic leukemia by site of careJulie A Wolfson, Smita Bhatia, Jill Ginsberg, et al.
Respiratory Research|May 31, 2020
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsGary T Ferguson, Nicola Brown, Chris Compton, et al.
Journal of Women'S Health (2002)|April 22, 2021
Sex-Based Differences in COVID-19 OutcomesAstha Tejpal, Eugenia Gianos, Jane Cerise, et al.
Journal of Viral Hepatitis|April 14, 2019
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosisFred Poordad, Shahriar Sedghi, Paul J Pockros, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 29, 2014
Management of acute loss of asthma control in the yellow zone: a practice parameterChitra Dinakar, John Oppenheimer, Jay Portnoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Modernizing Eligibility Criteria for Molecularly Driven TrialsEdward S Kim, David Bernstein, Susan G Hilsenbeck, et al.
The Science of the Total Environment|March 14, 2019
Using high-resolution residential greenspace measures in an urban environment to assess risks of allergy outcomes in childrenRebecca Gernes, Cole Brokamp, Glenn E Rice, et al.
Hepatology (Baltimore, Md.)|January 23, 2016
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized studyPaul Kwo, Norman Gitlin, Ronald Nahass, et al.
Pageof 15